Researchers have developed VIRE, a database that integrates approximately 1.7 million viral genomes derived from more than ...

Some brain disorders are straightforward, such as the direct frontal lobe assault of a concussion or traumatic brain injury.

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...

A DGIST research team identified that the mutation of the collybistin protein found in autistic patients weakens the brain's ...

Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA ...

With a new study in the journal Cell, researchers at Stanford University and Stockholm University have contributed to ...

Researchers have found a small but powerful switch inside breast cancer cells that helps them survive stressful conditions.

The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.

The FDA has approved Novartis’ Itvisma (onasemnogene abeparvovec-brve) for the treatment of adolescents two years and older, teens, and adults living with spinal muscular atrophy (SMA) with a ...

The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

Glucocorticoid replacement therapy is the current standard of care for congenital adrenal hyperplasia (CAH). However, new therapeutic strategies that can better recapitulate physiological requirements ...

Scientists have uncovered a genetic overlap between people and golden retrievers that helps explain why both species can be ...